Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) EPS (Basic) (2016 - 2025)

Vistagen Therapeutics' EPS (Basic) history spans 12 years, with the latest figure at -$0.45 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 2.17% year-over-year to -$0.45; the TTM value through Dec 2025 reached -$1.91, down 29.05%, while the annual FY2025 figure was -$1.67, 9.87% down from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.45 at Vistagen Therapeutics, up from -$0.55 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.33 in Q4 2023 and bottomed at -$2.04 in Q3 2021.
  • The 4-year median for EPS (Basic) is -$0.45 (2025), against an average of -$0.58.
  • The largest annual shift saw EPS (Basic) tumbled 3980.0% in 2021 before it surged 62.77% in 2024.
  • A 4-year view of EPS (Basic) shows it stood at -$1.59 in 2021, then skyrocketed by 120.72% to $0.33 in 2023, then plummeted by 239.39% to -$0.46 in 2024, then increased by 2.17% to -$0.45 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's EPS (Basic) are -$0.45 (Q4 2025), -$0.55 (Q3 2025), and -$0.47 (Q2 2025).